Cold Start Therapeutics enables rational, target-first hit discovery for yet-to-be liganded targets through our computational biophysics platform's ability to reveal previously invisible pocket motion
Cold Start Therapeutics enables rational, target-first hit discovery for yet-to-be liganded targets through our computational biophysics platform's ability to reveal previously invisible pocket motion. Our technology has uniquely enabled our diverse pipeline that includes a pan-mutant, wild-type sparing, beta-catenin molecule glue degrader program, Myc molecular glue degrader program, and a GLP-1R, GIPR, GCGR (triple G) small molecule agonist program.